Evidence map›Paper›PMID 27300702›Full record

ArticleJIMD reports2017

A Multiplatform Metabolomics Approach to Characterize Plasma Levels of Phenylalanine and Tyrosine in Phenylketonuria.

H Blasco, C Veyrat-Durebex, M Bertrand, F Patin, F Labarthe, H Henique, P Emond, C R Andres, C Antar, C Landon and 2 more

Abstract read
In one paragraph

Article in JIMD reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Metabolomic profiling in phenylketonuria: a systematic review of human studies.Metabolomics : Official journal of the Metabolomic Society · 2026
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

H BlascoLaboratoire de biochimie et biologie moléculaire, Hôpital Bretonneau, CHRU de Tours, 2, Bd Tonnellé, 37044, Tours cedex 1, France. helene.blasco@univ-tours.fr.
C Veyrat-DurebexLaboratoire de biochimie et biologie moléculaire, Hôpital Bretonneau, CHRU de Tours, 2, Bd Tonnellé, 37044, Tours cedex 1, France.
M BertrandCentre de Biophysique Moléculaire, CNRS UPR4301, Orléans, France.
F PatinLaboratoire de biochimie et biologie moléculaire, Hôpital Bretonneau, CHRU de Tours, 2, Bd Tonnellé, 37044, Tours cedex 1, France.
F LabartheService de Pédiatrie, CHRU de Tours, Tours cedex 1, France.
H HeniqueService de médecine interne, CHRU de Tours, Tours cedex 1, France.
P EmondINSERM U930, Université François Rabelais Tours, Tours cedex 1, France.
C R AndresLaboratoire de biochimie et biologie moléculaire, Hôpital Bretonneau, CHRU de Tours, 2, Bd Tonnellé, 37044, Tours cedex 1, France.
C AntarLaboratoire de biochimie et biologie moléculaire, Hôpital Bretonneau, CHRU de Tours, 2, Bd Tonnellé, 37044, Tours cedex 1, France.
C LandonCentre de Biophysique Moléculaire, CNRS UPR4301, Orléans, France.
L Nadal-DesbaratsINSERM U930, Université François Rabelais Tours, Tours cedex 1, France.
F MaillotINSERM U1069, Université François Rabelais Tours, Tours cedex 1, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDifferent pathophysiological mechanisms have been described in phenylketonuria (PKU) but the indirect metabolic consequences of metabolic disorders caused by elevated Phe or low Tyr concentrations remain partially unknown. We used a multiplatform metabolomics approach to evaluate the metabolic signature associated with Phe and Tyr. MATERIAL AND

methodsWe prospectively included 10 PKU adult patients and matched controls. We analysed the metabolome profile using GC-MS (urine), amino-acid analyzer (urine and plasma) and nuclear magnetic resonance spectroscopy (urine). We performed a multivariate analysis from the metabolome (after exclusion of Phe, Tyr and directly derived metabolites) to explain plasma Phe and Tyr concentrations, and the clinical status. Finally, we performed a univariate analysis of the most discriminant metabolites and we identified the associated metabolic pathways.

resultsWe obtained a metabolic pattern from 118 metabolites and we built excellent multivariate models to explain Phe, Tyr concentrations and PKU diagnosis. Common metabolites of these models were identified: Gln, Arg, succinate and alpha aminobutyric acid. Univariate analysis showed an inverse correlation between Arg, alpha aminobutyric acid and Phe and a positive correlation between Arg, succinate, Gln and Tyr (p < 0.0003). Thus, we highlighted the following pathways: Arg and Pro, Ala, Asp and Glu metabolism. DISCUSSION: We obtain a specific metabolic signature related to Tyr and Phe concentrations. We confirmed the involvement of different pathophysiological mechanisms previously described in PKU such as protein synthesis, energetic metabolism and oxidative stress. The metabolomics approach is relevant to explore PKU pathogenesis.

Indexed as

BiomarkersMetabolomicsNMRPhenylketonuria

Identifiers

PMID27300702
PMCPMC5362559

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.